MX2009006091A - Uso de agonistas de interlucina-27 para reducir aborto inmunomediado. - Google Patents

Uso de agonistas de interlucina-27 para reducir aborto inmunomediado.

Info

Publication number
MX2009006091A
MX2009006091A MX2009006091A MX2009006091A MX2009006091A MX 2009006091 A MX2009006091 A MX 2009006091A MX 2009006091 A MX2009006091 A MX 2009006091A MX 2009006091 A MX2009006091 A MX 2009006091A MX 2009006091 A MX2009006091 A MX 2009006091A
Authority
MX
Mexico
Prior art keywords
agonists
immune mediated
reduce immune
abortion
mediated abortion
Prior art date
Application number
MX2009006091A
Other languages
English (en)
Spanish (es)
Inventor
Odile Devergne
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009006091A publication Critical patent/MX2009006091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2009006091A 2006-12-07 2007-12-05 Uso de agonistas de interlucina-27 para reducir aborto inmunomediado. MX2009006091A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86903506P 2006-12-07 2006-12-07
PCT/US2007/024869 WO2008070097A1 (en) 2006-12-07 2007-12-05 Use of il-27 agonists to reduce immune mediated abortion

Publications (1)

Publication Number Publication Date
MX2009006091A true MX2009006091A (es) 2009-08-18

Family

ID=39185969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006091A MX2009006091A (es) 2006-12-07 2007-12-05 Uso de agonistas de interlucina-27 para reducir aborto inmunomediado.

Country Status (6)

Country Link
US (1) US20100150862A1 (OSRAM)
EP (1) EP2091555A1 (OSRAM)
JP (2) JP2010511710A (OSRAM)
CA (1) CA2671697A1 (OSRAM)
MX (1) MX2009006091A (OSRAM)
WO (1) WO2008070097A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784807B2 (en) 2006-09-22 2014-07-22 St. Jude Children's Research Hospital Method of inhibiting regulatory T-cell activity by administering an antibody that inhibits interleukin 35
EP2470566A1 (en) * 2009-08-24 2012-07-04 St. Jude Children's Research Hospital Compositions and methods for potentiating interleukin-35
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
WO2011063198A2 (en) 2009-11-20 2011-05-26 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
EP2513308B1 (en) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation of pilr to treat immune disorders
EP2687851A1 (en) * 2012-07-20 2014-01-22 Matricelab Innove Method for increasing implantation success in assisted fertilization
CA2918196A1 (en) * 2013-04-11 2014-10-16 The Brigham And Women's Hospital, Inc. Methods and compositions of treating autoimmune diseases
US12404494B2 (en) 2019-10-15 2025-09-02 Spinalcyte, Llc Prevention of recurrent miscarriages through administration of fibroblasts and fibroblast-educated paternal cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830451A (en) * 1996-07-19 1998-11-03 Brigham & Women's Hospital, Inc. Haematopoietic cytokine Epstein Barr virus-induced protein
ES2405506T3 (es) * 2003-10-24 2013-05-31 Nora Therapeutics, Inc. Un método para obtener datos útiles en la identificación de un paciente con riesgo de tener dificultad de llevar a término un embarazo

Also Published As

Publication number Publication date
CA2671697A1 (en) 2008-06-12
JP2010511710A (ja) 2010-04-15
US20100150862A1 (en) 2010-06-17
JP2013018794A (ja) 2013-01-31
EP2091555A1 (en) 2009-08-26
WO2008070097A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
MX2009006091A (es) Uso de agonistas de interlucina-27 para reducir aborto inmunomediado.
MY191118A (en) Use of non-digestible saccharides for giving an infant the best start after birth
CL2009001528S1 (es) Automovil de competicion formado por un cuerpo anterior trapecial alargado de perfil curvo convexo y un cuerpo posterior trapecial de vertices basales redondeados que en su cara superior presenta una cavidad, a partir de la cual la superficie se rebaja en sus laterales.
WO2008046050A3 (en) Method and apparatus for occluding a lumen
WO2013009674A3 (en) Intraurinary systems, iud insertion devices, and related methods and kits therefor
WO2018200481A8 (en) Methods of making improved human intestinal organoid compositions via application of strain and human intestinal organoid compositions thereof
GB2460008A (en) Bra and/or bra pad for providing the appearance of symmetry to asymmetrical breasts
CL2009000769A1 (es) Uso de un probiotico para mamiferos hembras embarazadas y potenciar la inmunidad de su progenie despues del nacimiento.
EP4008279A3 (en) System and method for intrauterine insemination
NZ601645A (en) Methods for improving sperm functionality comprising a pegylated binding agent
IN2012DN01538A (OSRAM)
GEP20166430B (en) Treatment of excessive menstrual bleeding associated with uterine fibroids
CL2012003105A1 (es) Bacteria comensal geneticamente diseñada, del tracto genital femenino que expresa un agente anti espermatozoide; composicion que comprende dicha bacteria; uso de dicha composicion para la reduccion de la incidencia de embarazo en una poblacion femenina; dispositivo de insercion intravaginal.
AU318075S (en) Cabin for working vehicles
EP2471538A4 (en) USE OF LPA TO PROMOTE PREGNANCY AND FERTILITY AGENT
RU2010111279A (ru) Способ профилактики стресса у женщин в родах
CA198299S (en) Vaginal ring for estrus synchronization in the cow
IL299066A (en) Vaginal gel
UA39650U (uk) Спосіб прогнозування розвитку внутрішньоутробного інфікування плоду
HK40091553B (zh) 阴道凝胶
UA37940U (ru) Способ прерывания беременности на поздних сроках
PH32020050184S1 (en) Vaginal Ring for Estrus Synchronization in the Cow
UA32373A (uk) Спосіб реабілітації жінок, які перенесли атонічні маткові кровотечі з акушерською гістеректомією
UA41029U (en) Use of m- and p-imidophenyl(meth)acrylates as polystyrene antioxidants
UA46198U (ru) Способ прогнозирования прогрессирования фиброзно-кистозной патологии молочных желез в период беременности

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: NEKTAR THERAPEUTICS

FA Abandonment or withdrawal